Collection 3 (Sep 2022 - Aug 2023) Articles

Articles
Lipid distributions in the Global Diagnostics Network across five continents
Martin SS, Niles JK, Kaufman HW, et al.
Journal:
Eur Heart J

First published: July 1, 2023 DOI: 10.1093/eurheartj/ehad371
View
- Share
Articles
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
Nissen SE, Menon V, Nicholls SJ, et al.
Journal:
JAMA

First published: June 24, 2023 DOI: 10.1001/jama.2023.9696
View
- Share
Articles
Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT
Shah NP, McGuire DK, Cannon CP, et al.
Journal:
J Am Heart Assoc

First published: June 22, 2023 DOI: 10.1161/JAHA.122.029593
View
- Share
Articles
Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients
Toplak H, Bilitou A, Alber H, et al.
Journal:
Wien Klin Wochenschr

First published: June 8, 2023 DOI: 10.1007/s00508-023-02221-4
View
- Share
Articles
High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?
Simonen P, Öörni K, Sinisalo J, et al.
Journal:
Atherosclerosis

First published: June 2, 2023 DOI: 10.1016/j.atherosclerosis.2023.06.003
View
- Share
Articles
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Kirkpatrick CF, Sikand G, Petersen KS, et al.
Journal:
J Clin Lipidol

First published: June 2, 2023 DOI: 10.1016/j.jacl.2023.05.099
View
- Share
Articles
Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers
Tokgozoglu L, Morrow DA, Nicholls SJ
Journal:
Eur Heart J

First published: June 1, 2023 DOI: 10.1093/eurheartj/ehad275
View
- Share
Articles
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial
Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.
Journal:
J Clin Lipidol

First published: May 31, 2023 DOI: 10.1016/j.jacl.2023.05.098
View
- Share
Articles
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
Gilliland TC, Liu Y, Mohebi R, et al.
Journal:
J Am Coll Cardiol

First published: May 9, 2023 DOI: 10.1016/j.jacc.2023.02.050
View
- Share
Articles
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program
Vassy JL, Posner DC, Ho YL, et al.
Journal:
JAMA Cardiol

First published: May 3, 2023 DOI: 10.1001/jamacardio.2023.0857
View
- Share
Articles
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
Cuchel M, Raal FJ, Hegele RA, et al.
Journal:
Eur Heart J

First published: May 2, 2023 DOI: 10.1093/eurheartj/ehad197
View
- Share
Articles
From the EAS: frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
Kronenberg F, Mora S, Stroes ESG, et al.
Journal:
Atherosclerosis

First published: April 28, 2023 DOI: 10.1016/j.atherosclerosis.2023.04.012
View
- Share

1 2 3 4 … 8

Collection 3 (Sep 2022 - Aug 2023) Articles

Articles

Lipid distributions in the Global Diagnostics Network across five continents

Martin SS, Niles JK, Kaufman HW, et al.

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen SE, Menon V, Nicholls SJ, et al.

Articles

Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT

Shah NP, McGuire DK, Cannon CP, et al.

Articles

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

Toplak H, Bilitou A, Alber H, et al.

Articles

High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?

Simonen P, Öörni K, Sinisalo J, et al.

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Articles

Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers

Tokgozoglu L, Morrow DA, Nicholls SJ

Articles

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.

Articles

Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes

Gilliland TC, Liu Y, Mohebi R, et al.

Articles

Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program

Vassy JL, Posner DC, Ho YL, et al.

Articles

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

Cuchel M, Raal FJ, Hegele RA, et al.

Articles

From the EAS: frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

Kronenberg F, Mora S, Stroes ESG, et al.

Articles

Lipid distributions in the Global Diagnostics Network across five continents

Martin SS, Niles JK, Kaufman HW, et al.

Share

Articles

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen SE, Menon V, Nicholls SJ, et al.

Share

Articles

Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT

Shah NP, McGuire DK, Cannon CP, et al.

Share

Articles

Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients

Toplak H, Bilitou A, Alber H, et al.

Share

Articles

High cholesterol absorption: A risk factor of atherosclerotic cardiovascular diseases?

Simonen P, Öörni K, Sinisalo J, et al.

Share

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Share

Articles

Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers

Tokgozoglu L, Morrow DA, Nicholls SJ

Share

Articles

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Ballantyne CM, Ditmarsch M, Kastelein JJ, et al.

Share

Articles

Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes

Gilliland TC, Liu Y, Mohebi R, et al.

Share

Articles

Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program

Vassy JL, Posner DC, Ho YL, et al.

Share

Articles

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

Cuchel M, Raal FJ, Hegele RA, et al.

Share

Articles

From the EAS: frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

Kronenberg F, Mora S, Stroes ESG, et al.

Share